Literature DB >> 11850246

Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.

Sylvia Valdezate1, Ana Vindel, Aurora Echeita, Fernando Baquero, Rafael Cantó.   

Abstract

The quinolone resistance-determining regions (QRDRs) of topoisomerase II and IV genes from Stenotrophomonas maltophilia ATCC 13637 were sequenced and compared with the corresponding regions of 32 unrelated S. maltophilia clinical strains for which ciprofloxacin MICs ranged from 0.1 to 64 microg/ml. GyrA (Leu-55 to Gln-155, Escherichia coli numbering), GyrB (Met-391 to Phe-513), ParC (Ile-34 to Arg-124), and ParE (Leu-396 to Leu-567) fragments from strain ATCC 13637 showed high degrees of identity to the corresponding regions from the phytopathogen Xylella fastidiosa, with the degrees of identity ranging from 85.0 to 93.5%. Lower degrees of identity to the corresponding regions from Pseudomonas aeruginosa (70.9 to 88.6%) and E. coli (73.0 to 88.6%) were observed. Amino acid changes were present in GyrA fragments from 9 of the 32 strains at positions 70, 85, 90, 103, 112, 113, 119, and 124; but there was no consistent relation to higher ciprofloxacin MICs. The absence of changes at positions 83 and 87, commonly involved in quinolone resistance in gram-negative bacteria, was unexpected. The GyrB sequences were identical in all strains, and only one strain (ciprofloxacin MIC, 16 microg/ml) showed a ParC amino acid change (Ser-80-->Arg). In contrast, a high frequency (16 of 32 strains) of amino acid replacements was present in ParE. The frequencies of alterations at positions 437, 465, 477, and 485 were higher (P < 0.05) in strains from cystic fibrosis patients, but these changes were not linked with high ciprofloxacin MICs. An efflux phenotype, screened by the detection of decreases of at least twofold doubling dilutions of the ciprofloxacin MIC in the presence of carbonyl cyanide m-chlorophenylhydrazone (0.5 microg/ml) or reserpine (10 microg/ml), was suspected in seven strains. These results suggest that topoisomerases II and IV may not be the primary targets involved in quinolone resistance in S. maltophilia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850246      PMCID: PMC127482          DOI: 10.1128/AAC.46.3.665-671.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region.

Authors:  S M Friedman; T Lu; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.

Authors:  H Mouneimné; J Robert; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Pharmacokinetics and pharmacodynamics of newer fluoroquinolones.

Authors:  G E Stein
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

5.  Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium.

Authors:  J Ruiz; D Castro; P Goñi; J A Santamaria; J J Borrego; J Vila
Journal:  J Med Microbiol       Date:  1997-07       Impact factor: 2.472

6.  Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.

Authors:  Y Wang; W M Huang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Authors:  P Heisig; H Schedletzky; H Falkenstein-Paul
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.

Authors:  J Vila; J Ruiz; F Marco; A Barcelo; P Goñi; E Giralt; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

Authors:  S Valdezate; A Vindel; L Maiz; F Baquero; H Escobar; R Cantón
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  15 in total

1.  Regulatory regions of smeDEF in Stenotrophomonas maltophilia strains expressing different amounts of the multidrug efflux pump SmeDEF.

Authors:  Patricia Sanchez; Ana Alonso; Jose L Martinez
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  Phenotypic and molecular characterization of Acinetobacter clinical isolates obtained from inmates of California correctional facilities.

Authors:  Galarah D Golanbar; Christopher K Lam; Yi-Ming Chu; Carla Cueva; Stephanie W Tan; Isba Silva; H Howard Xu
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

3.  Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains.

Authors:  Federico Román; Rafael Cantón; María Pérez-Vázquez; Fernando Baquero; José Campos
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Whole-genome sequencing identifies emergence of a quinolone resistance mutation in a case of Stenotrophomonas maltophilia bacteremia.

Authors:  Theodore R Pak; Deena R Altman; Oliver Attie; Robert Sebra; Camille L Hamula; Martha Lewis; Gintaras Deikus; Leah C Newman; Gang Fang; Jonathan Hand; Gopi Patel; Fran Wallach; Eric E Schadt; Shirish Huprikar; Harm van Bakel; Andrew Kasarskis; Ali Bashir
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

5.  Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California.

Authors:  Sonya C Valentine; Deisy Contreras; Stephanie Tan; Lilian J Real; Sheena Chu; H Howard Xu
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

Review 6.  Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia.

Authors:  María B Sánchez
Journal:  Front Microbiol       Date:  2015-06-30       Impact factor: 5.640

7.  Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.

Authors:  Wei Jia; Jiayuan Wang; Haotong Xu; Gang Li
Journal:  Int J Environ Res Public Health       Date:  2015-05-13       Impact factor: 3.390

Review 8.  Mechanism of action of and resistance to quinolones.

Authors:  Anna Fàbrega; Sergi Madurga; Ernest Giralt; Jordi Vila
Journal:  Microb Biotechnol       Date:  2008-10-13       Impact factor: 5.813

9.  Correlation between virulence genotype and fluoroquinolone resistance in carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Hye Hyun Cho; Kye Chul Kwon; Semi Kim; Sun Hoe Koo
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

10.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.